Efficient Downstream Processing Of Antibody-Based Therapeutics – A CDMO Perspective

Achieving truly efficient downstream processing for antibody-based therapeutics requires more than just standardized unit operations. While traditional purification schemes for monoclonal antibodies are well-established, variables from molecule characteristics to facility fit significantly impact outcomes like purity, yield, speed, and cost.

In this conversational webinar, Robin Dothager, Senior Manager of Process Development at Patheon (part of Thermo Fisher), shares his CDMO expertise with Thermo Fisher’s Buzz Lobbezoo. Drawing on Robin’s extensive experience meeting diverse customer requirements in antibody purification, they explore key considerations for mAbs and multispecifics. Gain insights into navigating trade-offs between speed, cost, purity, and yield, and discover strategies for addressing challenging molecules.

For practical advice on optimizing your antibody downstream processing from a CDMO perspective, watch this webinar today.